|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NCOA5 |
Gene summary for NCOA5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NCOA5 | Gene ID | 57727 |
| Gene name | nuclear receptor coactivator 5 | |
| Gene Alias | CIA | |
| Cytomap | 20q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9HCD5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57727 | NCOA5 | LZE24T | Human | Esophagus | ESCC | 1.91e-12 | 2.40e-01 | 0.0596 |
| 57727 | NCOA5 | P1T-E | Human | Esophagus | ESCC | 2.13e-09 | 3.83e-01 | 0.0875 |
| 57727 | NCOA5 | P2T-E | Human | Esophagus | ESCC | 1.20e-19 | 3.00e-01 | 0.1177 |
| 57727 | NCOA5 | P4T-E | Human | Esophagus | ESCC | 8.19e-11 | 2.29e-01 | 0.1323 |
| 57727 | NCOA5 | P5T-E | Human | Esophagus | ESCC | 3.06e-06 | 1.72e-01 | 0.1327 |
| 57727 | NCOA5 | P8T-E | Human | Esophagus | ESCC | 6.86e-09 | 2.09e-01 | 0.0889 |
| 57727 | NCOA5 | P9T-E | Human | Esophagus | ESCC | 2.86e-04 | 1.77e-01 | 0.1131 |
| 57727 | NCOA5 | P10T-E | Human | Esophagus | ESCC | 2.69e-28 | 5.08e-01 | 0.116 |
| 57727 | NCOA5 | P11T-E | Human | Esophagus | ESCC | 2.30e-09 | 2.90e-01 | 0.1426 |
| 57727 | NCOA5 | P12T-E | Human | Esophagus | ESCC | 4.99e-29 | 5.48e-01 | 0.1122 |
| 57727 | NCOA5 | P15T-E | Human | Esophagus | ESCC | 7.80e-15 | 3.34e-01 | 0.1149 |
| 57727 | NCOA5 | P16T-E | Human | Esophagus | ESCC | 2.19e-13 | 3.22e-01 | 0.1153 |
| 57727 | NCOA5 | P17T-E | Human | Esophagus | ESCC | 9.46e-05 | 2.83e-01 | 0.1278 |
| 57727 | NCOA5 | P20T-E | Human | Esophagus | ESCC | 2.85e-19 | 4.21e-01 | 0.1124 |
| 57727 | NCOA5 | P21T-E | Human | Esophagus | ESCC | 3.13e-09 | 2.29e-01 | 0.1617 |
| 57727 | NCOA5 | P22T-E | Human | Esophagus | ESCC | 1.26e-08 | 2.29e-01 | 0.1236 |
| 57727 | NCOA5 | P23T-E | Human | Esophagus | ESCC | 4.10e-11 | 3.05e-01 | 0.108 |
| 57727 | NCOA5 | P24T-E | Human | Esophagus | ESCC | 4.91e-05 | 1.76e-01 | 0.1287 |
| 57727 | NCOA5 | P26T-E | Human | Esophagus | ESCC | 5.19e-22 | 4.19e-01 | 0.1276 |
| 57727 | NCOA5 | P27T-E | Human | Esophagus | ESCC | 8.64e-08 | 2.12e-01 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190165319 | Esophagus | ESCC | cellular response to peptide | 208/8552 | 359/18723 | 1.68e-06 | 2.01e-05 | 208 |
| GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
| GO:003286918 | Esophagus | ESCC | cellular response to insulin stimulus | 124/8552 | 203/18723 | 6.63e-06 | 6.75e-05 | 124 |
| GO:003286818 | Esophagus | ESCC | response to insulin | 156/8552 | 264/18723 | 7.21e-06 | 7.20e-05 | 156 |
| GO:007137516 | Esophagus | ESCC | cellular response to peptide hormone stimulus | 166/8552 | 290/18723 | 4.48e-05 | 3.55e-04 | 166 |
| GO:00082869 | Esophagus | ESCC | insulin receptor signaling pathway | 66/8552 | 116/18723 | 9.76e-03 | 3.37e-02 | 66 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NCOA5 | SNV | Missense_Mutation | c.43N>A | p.Pro15Thr | p.P15T | Q9HCD5 | protein_coding | deleterious_low_confidence(0.02) | benign(0.04) | TCGA-A2-A0CW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| NCOA5 | SNV | Missense_Mutation | novel | c.576N>G | p.Phe192Leu | p.F192L | Q9HCD5 | protein_coding | tolerated(0.11) | benign(0.199) | TCGA-A7-A4SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| NCOA5 | SNV | Missense_Mutation | novel | c.642N>C | p.Glu214Asp | p.E214D | Q9HCD5 | protein_coding | deleterious(0.01) | probably_damaging(0.909) | TCGA-AC-A3W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
| NCOA5 | SNV | Missense_Mutation | c.703N>C | p.Glu235Gln | p.E235Q | Q9HCD5 | protein_coding | tolerated(0.11) | probably_damaging(0.99) | TCGA-AR-A24U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| NCOA5 | SNV | Missense_Mutation | novel | c.446N>C | p.Arg149Thr | p.R149T | Q9HCD5 | protein_coding | deleterious(0.03) | possibly_damaging(0.586) | TCGA-B6-A0RT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NCOA5 | SNV | Missense_Mutation | rs758269352 | c.583N>A | p.Glu195Lys | p.E195K | Q9HCD5 | protein_coding | deleterious(0.01) | possibly_damaging(0.839) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NCOA5 | SNV | Missense_Mutation | rs370602943 | c.35G>A | p.Arg12Gln | p.R12Q | Q9HCD5 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.979) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| NCOA5 | SNV | Missense_Mutation | c.945G>C | p.Lys315Asn | p.K315N | Q9HCD5 | protein_coding | tolerated(0.09) | probably_damaging(0.976) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| NCOA5 | SNV | Missense_Mutation | novel | c.428N>G | p.Ser143Cys | p.S143C | Q9HCD5 | protein_coding | deleterious(0.02) | benign(0.068) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NCOA5 | SNV | Missense_Mutation | c.556N>A | p.Glu186Lys | p.E186K | Q9HCD5 | protein_coding | deleterious(0.01) | benign(0.121) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |